Intranasal erythropoietin therapy in nervous system disorders
Source: Expert Opinion on Drug Delivery, Volume 8, Number 1, January 2011 , pp. 19-32(14)
Publisher: Informa Healthcare
Abstract:Importance of the field: Erythropoietin (EPO) is a growth hormone and cytokine that plays an important role in erythropoiesis and neuroprotection. However, EPO treatment for neurological diseases requires repeated injections or high-dose systemic administration, which may cause systemic side effects. The lack of any effective treatment of acute and chronic neurodegenerative diseases and the promising outcome by EPO in animal models in vivo demand a critical evaluation of intranasal EPO delivery to the brain as an alternative administration method.
Areas covered in this review: The current use and intranasal administration of EPO and its derivatives in preclinical studies and recent clinical trials with EPO in neurological diseases.
What the reader will gain: This paper gives an overview of the therapeutic considerations of intranasal EPO and EPO derivatives for neuroprotection.
Take home message: Intranasal delivery (ID) of neuroprotective drugs is an area of great interest. Among the administration strategies used at present, ID of EPO is the most promising. Further preclinical and clinical studies are needed to evaluate the potential significance of this alternative route for increasing EPO bioavailability and decreasing side effects.
Document Type: Research Article
Affiliations: 1: 1Dokuz Eylul University, Health Science Institute, Department of Neuroscience, Inciralti, 35340, Izmir, Turkey +90 232 412 4676; +90 232 277 65 84;, Email: firstname.lastname@example.org 2: 2University of Texas, Health Science Center, Department of Neurosurgery and Physiology, San Antonio, TX, 78229, USA
Publication date: January 1, 2011